Evidence map›Paper›PMID 36768209›Full record

ReviewInternational journal of molecular sciences2023

Oligorecurrent Non-Small-Cell Lung Cancer Treated by Chemo-Radiation Followed by Immunotherapy and Intracranial Radiosurgery: A Case Report and Mini Review of Literature.

Alessio Bruni, Federica Bertolini, Elisa D'Angelo, Giorgia Guaitoli, Jessica Imbrescia, Anna Cappelli, Gabriele Guidi, Alessandro Stefani, Massimo Dominici, Frank Lohr

Abstract readReviewCase Reports
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alessio BruniRadiation Oncology Unit, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy.ORCID 0000-0003-1068-5958
Federica BertoliniDivision of Oncology, Department of Oncology and Hematology, Modena University Hospital, 41124 Modena, Italy.ORCID 0000-0002-8112-2936
Elisa D'AngeloRadiation Oncology Unit, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy.ORCID 0000-0002-5954-0939
Giorgia GuaitoliDivision of Oncology, Department of Oncology and Hematology, Modena University Hospital, 41124 Modena, Italy.ORCID 0000-0001-8671-9910
Jessica ImbresciaRadiation Oncology Unit, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy.
Anna CappelliRadiation Oncology Unit, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy.
Gabriele GuidiMedical Physics Unit, University Hospital of Modena, 41124 Modena, Italy.ORCID 0000-0001-9535-9152
Alessandro StefaniDivision of Thoracic Surgery, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41124 Modena, Italy.
Massimo DominiciDivision of Oncology, Department of Oncology and Hematology, Modena University Hospital, 41124 Modena, Italy.
Frank LohrRadiation Oncology Unit, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Locally advanced non-small-cell lung cancer still represents a "grey zone" in terms of the best treatment choice and optimal clinical outcomes. Indeed, most patients may be suitable to receive different treatments with similar outcomes such as chemo-radiotherapy (CHT-RT) followed by immunotherapy (IO) or surgery followed by adjuvant local/systemic therapies. We report a clinical case of a patient submitted to primary thoracic surgery who developed a mediastinal nodal recurrence successfully treated by CHT-RT-IO. Subsequently, a single brain lesion was found to have been successfully treated by single fraction stereotactic ablative radiotherapy. The patient is still on follow-up and she is free from disease having a good quality of life. In this report, we also perform a mini review about the role of CHT-RT followed by IO in treating loco-regional relapse after surgery. The role of SABR after IO is also evaluated, finding that it is safe and well tolerated. More robust and larger clinical data are needed in this particular setting to better define the role of the combination of systemic and local treatments in the management of intrathoracic and intracranial relapse for patients already submitted to CHT-RT followed by immunotherapy.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsRadiosurgeryFemaleHumansImmunotherapyQuality of LifeRecurrencechemo-radiotherapyimmunotherapyNSCLCSABR

Identifiers

PMID36768209
PMCPMC9915407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.